VA 2
Alternative Names: VA-2Latest Information Update: 17 Jun 2025
At a glance
- Originator Valorum Biologics
- Class Antineoplastics
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase III Cancer
Most Recent Events
- 17 Jun 2025 Phase-III clinical trials in Cancer in USA before May 2025 (unspecified route) (Valorum Biologics pipeline, June 2025)